pharma news

News

GLP-1 drugs for weight loss, cancer, and rare diseases feature among the latest crop of medicines awarded priority vouchers by the FDA.

News

The pricing agreement between Novo Nordisk and Eli Lilly and the Trump administration on GLP-1 drugs for diabetes and obesity has arrived.

News

Johnson & Johnson has clinched an FDA approval for Caplyta in depression, satisfying a major driver for its $14.6bn takeover of ICT this year.

News

Eli Lilly has raised the stakes in the obesity market with positive midstage data for its amylin-targeting drug eloralintide.

News

AstraZeneca takes another step forwards towards its target of growing revenues to $80bn by 2030, as quarterly sales top $15bn for the first time.

News

Shortly after reporting weaker sales growth for its injectable GLP-1 drugs, Novo Nordisk has new data to help it stake a claim to the oral market.